U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811232) titled 'A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers' on Aug. 12.
Brief Summary: This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combination with one of three anticancer treatments: AL8326 (veonetinib), eribulin, or fulvestrant. Adults with recurrent, advanced, or metastatic endometrial cancer, cervical cancer, soft tissue sarcoma, or breast cancer may be eligible after at least one prior standard treatment has failed or could not be tolerated and no effective standard treatment option remains.
In phase 1b, small groups of participants will receive dif...